

THE CLINICAL EXCHANGE

Evaluation Form

Expert Perspectives on Treating and Managing Patients at High Risk for Fracture

This interactive, case-based program was developed by leading Canadian experts to address the importance of risk assessment, screening and management for all patients at high risk for stress fracture. This program aims to translate scientific and clinical evidence into practical steps and incorporates expert recommendations into practical strategies applicable to primary care practice.

DATE

2019/02/26

LOCATION

location

Demographics

Physician: ☐ Yes ☐ No ☐ Other Please specify _____

Type of Practice: ☐ Full-time ☐ Part-time ☐ Solo ☐ Group ☐ Office ☐ Hospital ☐ Other

LEARNING OBJECTIVES: The Clinical Exchange: Expert Perspectives on Treating and Managing Patients at High Risk for Fracture

After participating in this activity, I am now better able to:

1. Perform risk assessments and screening for all patients at high risk for fracture, including all male and female patients who are treatment naïve or currently on therapy

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

2. Translate scientific and clinical evidence into the management and treatment of all high risk patients in primary care practice

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

3. Integrate expert recommendations and practical strategies for future assessment, treatment and management of all patients at high risk for fracture

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

LEARNING OBJECTIVES: The Clinical Exchange: Expert Perspectives on Treating and Managing Patients at High Risk for Fracture – Core Deck

Upon completion of this case based session, participants will be able to:

1. Perform risk assessments and screening for all patients at high risk for fragility fracture, including all patients who are treatment naïve or currently on therapy

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

2. Translate scientific and clinical evidence into the management and treatment of all high risk patients in primary care practice

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

3. Integrate expert recommendations and practical strategies for future assessment, treatment and management of all patients at high risk for fragility fracture

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

LEARNING OBJECTIVES: Case 1 - Risk Assessment and Management of Treatment Naïve PMO Patients

Upon completion of this case based session, participants will be able to:

1. Identify clinical and diagnostic risk factors which further increase the risk of fractures in post menopausal women

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

2. Apply evidence based, guidelines and expert recommended management protocols to prevent future fractures in post menopausal women

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

3. Assess patients' on treatment for occurrence of side effects and select appropriate therapies based on the patient characteristics

Strongly disagree Disagree Neutral Agree Strongly agree
1 2 3 4 5

LEARNING OBJECTIVES: Case 2 - Risk Assessment & Management of Male OP Patients

Upon completion of this case based session, participants will be able to:

1. Identify social, clinical and diagnostic risk factors which further increase the risk of fractures specific to male patients

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Apply evidence based, guidelines and expert recommended management protocols to prevent future fractures in male patients

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Assess patients' on treatment for occurrence of side effects and select appropriate therapies based on the patient characteristics

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Case 3 - Medications and Comorbidities Associated with Bone Loss

Upon completion of this case based session, participants will be able to:

1. Explain the impact of co-morbidities and the mechanism of action on the risk profile of patients with osteoporosis

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Describe concomitant drug use which may contribute to further bone loss when assessing fracture risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Individualize relevant treatment strategies based on the patient's risk factors and co-morbid conditions

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Case 4 - Benefits of Treatment Persistence and Adherence

Upon completion of this case based session, participants will be able to:

1. Monitor OP treatment response, evaluate treatment efficacy and identify non-responders

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Assess patients' response to OP treatment including patient reported outcomes and identify management strategies to improve adherence

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Communicate the importance of treatment persistence to patients and providers

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Case 5 - Optimization of Long-Term Therapy

Upon completion of this case based session, participants will be able to:

1. Incorporate the history of prior fractures in determining future risk

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Assess the risk of falls as a major and independent risk for fractures

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Consider patient preference when selecting long term treatment

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

4. Explain the importance of adherence including avoidance of drug holidays in high risk individuals

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

Speaker sp1

Was effective in Presenting Material:

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No

If so, please explain: _____

Speaker sp2

Was effective in Presenting Material:

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

Did you perceive any degree of bias in any part of the program? ☐ Yes ☐ No

If so, please explain: _____

This Program

Content enhanced my knowledge

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Addressed my most pressing questions

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Promoted improvements or quality in health care

Strongly disagree	Neutral			Strongly agree
1	2	3	4	5

Was scientifically rigorous and evidence-based

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Provided appropriate and effective opportunities for active learning
(ie., case studies, discussion, Q & A, etc)

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Provided an opportunity for interaction with my peers

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Please indicate with CAnMEDS roles you felt were addressed during this educational activity.

- ☐ Family Medicine Expert
- ☐ Collaborator
- ☐ Communicator
- ☐ Manager
- ☐ Health Advocate
- ☐ Professional
- ☐ Scholar

Based on your participation in this program, please select all applicable statement(s):

- ☐ I gained new strategies/skills/information that I can apply to my area of practice.
- ☐ I plan to implement new strategies/skills/information into my practice.
- ☐ I need more information before I can implement new strategies/skills/information into my practice behavior
- ☐ This program will not change my practice, as my current practice is consistent with the information presented.
- ☐ This program will not change my practice, as I do not agree with the information presented.

What strategies/changes do you plan to implement into your practice?

What barriers do you see to making a change in your practice?

Future Topics of Interest / Additional Comment & Suggestions

Thank you for your feedback!

This program has received an educational grant and in-kind support from Amgen Canada